文献速递关节外科小儿骨科创伤骨科

早期全髋关节置换术是严重影像学股骨头骨骺滑脱患者终身期具成本效益的治疗

Early Total Hip Arthroplasty is a Cost-Effective Treatment for Severe Radiographic Slipped Capital Femoral Epiphysis Over an Individual's Lifetime.
PubMed 文献 · J Arthroplasty · 2022-12-05

该研究构建马尔可夫模型,比较严重稳定型股骨头骨骺滑脱(SCFE)患儿接受原位钉固定后转子间截骨(ISP+ITO)再行全髋关节置换(THA)与原位钉固定(ISPa)后早期THA的终身成本效益。60年时间范围内,ISPa组成本更高(291,836美元)但获得更多质量调整生命年(51.4 vs 48.7),增量成本效益比为80,980美元/QALY,低于社会支付意愿阈值100,000美元/QALY,结论为ISPa后早期THA具成本效益。

要点

  • 严重稳定型SCFE患儿60年模型显示,ISPa后早期THA的ICER为80,980美元/QALY,低于100,000美元/QALY的支付意愿阈值。
  • ISPa组成本291,836美元、获得51.4 QALYs,ISP+ITO组成本75,227美元、获得48.7 QALYs。
  • 植入物生存率和时间范围是模型的敏感变量。

核心结论

  • 基于当前植入物性能,考虑个体预期寿命,ISPa后早期THA具成本效益,值得在严重SCFE患者中考虑。

研究设计与样本

  • 构建状态转换马尔可夫模型,分析严重稳定型SCFE患儿接受ISPa或ISP+ITO在60年时间范围内的成本效益。
  • 模型参数(植入物和原生髋生存率、状态效用值、成本)来源于文献,并进行敏感性分析评估模型稳健性。
  • 证据等级为经济与决策分析,III级。

主要发现

  • 60年时间范围内,ISPa组成本为291,836美元,ISP+ITO组为75,227美元。
  • ISPa组获得51.4 QALYs,ISP+ITO组获得48.7 QALYs。
  • ISPa的增量成本效益比为80,980美元/QALY,低于100,000美元/QALY的社会支付意愿阈值,具成本效益。
  • 植入物生存率和时间范围是敏感变量。

关键数值与推荐

  • 成本效益阈值采用社会支付意愿100,000美元/QALY。
  • ISPa的ICER为80,980美元/QALY。
  • ISPa组成本291,836美元、51.4 QALYs;ISP+ITO组成本75,227美元、48.7 QALYs。

临床怎么用

  • 作者认为,基于当前植入物性能,ISPa后早期THA在考虑个体预期寿命时具成本效益,值得在严重SCFE患者中考虑。
  • 作者指出,在没有明确1级临床数据的情况下,该经济模型为家庭和临床医生理解治疗选择提供了框架。

局限性

  • 原文指出,在没有明确1级临床数据的情况下,该经济模型仅用于处理这一难题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Slipped capital femoral epiphysis (SCFE) causes degenerative changes warranting total hip arthroplasty (THA) in approximately 50% of patients by age 60 years. For severe SCFE, a reorienting intertrochanteric osteotomy (ITO) following in situ pinning (ISP) can decrease impingement with hip flexion, but by altering proximal femoral geometry, complicates subsequent conversion THA. We hypothesized that increasing implant survivorship would affect the most cost-effective treatment strategy (ISP followed by ITO [ISP + ITO] with later THA versus ISP alone [ISPa] with earlier THA) over a patient's lifetime. METHODS: A state-transition Markov model was constructed to analyze the cost-effectiveness of either ISPa or ISP + ITO over a 60-year time horizon for children who have severe, stable SCFE. Transition probabilities associated with implant and native hip survivorship, state utilities, and costs were derived from the literature. Sensitivity analyses assessed the model robustness. Incremental cost-effectiveness ratios (ICERs) were compared to a societal willingness to pay (WTP) of $100,000 per quality-adjusted life year (QALY). RESULTS: Over a 60-year horizon, ISPa was costlier ($291,836) than ISP + ITO ($75,227) but achieved overall better outcomes (51.4 QALYs ISPa versus 48.7 QALYs ISP + ITO), rendering ISPa cost-effective with an ICER of $80,980/QALY. Implant survivorship and time horizon were sensitive variables. CONCLUSION: Based upon current implant performance, ISPa with subsequent earlier THA is cost-effective when considering an individual's life expectancy and thereby deserves consideration in patients who have severe SCFE. Without clear level 1 clinical data, our economic model considers a difficult problem, while providing families and clinicians with a framework for understanding treatment options. LEVEL OF EVIDENCE: Economic and decision analysis, Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. de Araujo OB, Paranjape CS, Bracey DN, et al. Early Total Hip Arthroplasty is a Cost-Effective Treatment for Severe Radiographic Slipped Capital Femoral Epiphysis Over an Individual's Lifetime. J Arthroplasty. 2022. PMID: 36470363. doi:10.1016/j.arth.2022.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。